Nanoscope Validates Functional Vision Test for Retinal Degeneration Patients

Event summary

  • Nanoscope published a peer-reviewed study in Documenta Ophthalmologica validating the Multi-luminance Shape Discrimination Test (MLSDT) for assessing functional vision in severe retinal degeneration patients.
  • The study involved 35 subjects, including 25 with retinitis pigmentosa (RP) and 10 with normal vision.
  • MCO-010, Nanoscope's lead therapy, showed clinically meaningful improvements in MLSDT in a Phase 2b/3 trial.
  • Nanoscope is pursuing regulatory approvals for MCO-010 in RP and Stargardt disease (SD), with Phase 3 trials planned for 2026.

The big picture

Nanoscope's study highlights the growing need for more comprehensive vision assessment tools beyond best-corrected visual acuity (BCVA), particularly for patients with severe vision loss. The validation of MLSDT could set a new benchmark for measuring functional improvements in retinal degeneration therapies, potentially influencing regulatory standards and clinical practice. With ongoing regulatory submissions and planned Phase 3 trials, Nanoscope is positioning itself as a leader in optogenetic therapies for retinal diseases.

What we're watching

Regulatory Pathway
Whether Nanoscope's rolling BLA submission for MCO-010 will secure FDA approval and establish a new standard of care for RP patients.
Clinical Validation
The pace at which MLSDT becomes widely adopted as a supplementary assessment tool for functional vision in retinal degeneration.
Market Expansion
How Nanoscope will leverage its disease-agnostic platform to expand into other retinal degenerative diseases like geographic atrophy (GA) and Leber congenital amaurosis (LCA).

Related topics

Biotechnology